Onxeo SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
cross-border merger of Bioalliance Pharma SA and Topotarget is legally effective as of July 22, 2014
Bioalliance Pharma SA:Says that cross-border merger between two companies is legally effective as of July 22, 2014 to create Onxeo, dedicated to orphan oncology diseases.
Latest Developments for Onxeo SA
- Onxeo SA announces positive phase II preliminary results of Validive
- Bioalliance Pharma announces approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen following merger with TopoTarget
- Bioalliance Pharma SA announces FDA approval of Beleodaq
- Bioalliance Pharma and Topotarget shareholders approve merger proposal
- Share this
- Digg this